$100 Discount Code for Your First Order of 1 mg Cre Recombinase: CreDiscount

Discount for switching from competitors\' product: $150. Email to Tech Support ts@excellgen.com for discount code.

Cre recombinase, often abbreviated to Cre, is a Type I topoisomerase from P1 bacteriophage that catalyzes site-specific recombination of DNA between loxP sites. This enzyme does not require any energy cofactors, and Cre-mediated recombination quickly reaches equilibrium between substrate and reaction products. The loxP recognition element is a 34 base pair (bp) sequence composed of two 13 bp inverted repeats flanking an 8 bp spacer region which confers directionality. Recombination products are dependent on the location and relative orientation of the loxP sites. Two DNA species containing single loxP sites will be fused whilst DNA between loxP sites in the same orientation will be excised in circular form and DNA between opposing loxP sites will be inverted with respect to the rest of the DNA.

Cre recombinase is used as a tool to modify genes and chromosomes. In this approach the Cre recombinase is used to delete a segment of DNA flanked by LoxP sites (aka \'floxed\') in an experimental animal. It has been used to generate animals with mutations limited to certain cell types (tissue-specific knockout) or animals with mutations that can be activated by drug administration (inducible knockout) in a number of transgenic species. The availability of transgenic lines with tissue specific or inducible Cre expression permits researchers to inactivate or activate a gene of interest simply by breeding a floxed animal to pre-existing Cre-transgenics. One example of an inducible Cre recombinase system is the Cre-ER (ER = Estrogen Receptor) system in which intraperitoneal injection of tamoxifen will cause dose-dependent excision of the floxed site (i.e. will inactivate the gene of choice).

Recombinant Cre recombinase (TAT-Cre) was purified from an E. coli strain carrying an engineered plasmid encoding enhanced form of Cre Recombinase from bacteriophage P1. This Cre recombinase has an N-terminal 6XHis tag, a Tat peptide (GRKKRRQRRRPPAGTSVSL) and an NLS sequence (PKKKRKV). HTNC is the most effective protein in transduction (in vivo) and subsequent recombination compared to other forms of Cre recombinases, e.g., HNC, TCH6, HC, HNCM, CH. Incubation of fibroblast reporter cells with 1 μM HTNC for 1 to 2 hours can result in tranduction of 60 ~ 90% of the cells*. Addition of 100 μM choroquine to culture medium mayfurther enhance transduction and recombination.

* Use this page to calculate concentration required for culturedcells:http://www.excellgen.com/pub/mw_2_moles.html

• In vitro LoxP recombination for subcloning or vector/clone engineering

• Transduction into cultured cells including stem cells ex Vivo

Molecular Weight: 43 kDa

QC: Tat-Cre induced 80~100% recombination efficiencies in HEK293T- Cre reporter cells. HEK293T-cells were transfected with reporter plasmid DNA: LoxP-RFP-Stop-LoxP-GFP, then add 1 μM purified Tat-Cre protein.

Fig 1: 0: before adding Tat-Cre; 1 to 5: 1 to 5 days after transduction with Tat-Cre.

Endotoxin Levels: < 0.1 EU/μg

Purity: >98% by SDS-PAGE and HPLC analysis.

• 1. Integrin-Linked Kinase Regulates Process Extension in Oligodendrocytes via Control of Actin Cytoskeletal Dynamics, The Journal of Neuroscience, 5 June 2013, 33(23): 9781-9793; doi: 10.1523/​ JNEUROSCI.5582-12.2013
• 2. Cutting Edge: Krüppel-like Factor 2 Is Required for Phenotypic Maintenance but Not Development of B1 B Cells. The Journal of Immunology. August 31, 2012 1201439. doi: 10.4049/ ​jimmunol.1201439. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448866/
• 3. KINASE-INDEPENDENT FEEDBACK OF THE TAK1/TAB1 COMPLEX ON BCL10 TURNOVER AND NF-κB ACTIVATION. Mol. Cell. Biol. 2013. doi: 10.1128/MCB.06407-11
• 4. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nature Medicine 19, 488–493 (2013) doi:10.1038/nm.3092
• 5. T Cell−Derived IL-17 Mediates Epithelial Changes in the Airway and Drives Pulmonary Neutrophilia. J Immunol published online 21 August 2013 http://www.jimmunol.org/content/early/2013/08/21/jimmunol.1301360
• 6. Rapid conversion of EUCOMM/KOMP-CSD alleles in mouse embryos using a cell-permeable Cre recombinase. Transgenic Research. February 2014, Volume 23, Issue 1, pp 177-185. doi: 10.1007/s11248-013-9764-x NCBI: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890051/
• 7. Antibody-membrane switch (AMS) technology for facile cell line development.Protein Engineering, Design and Selection (2014) 27 (10): 309-315. doi: 10.1093/protein/gzu039
• 8. The role of antisense long noncoding RNA in small RNA-triggered gene activation. RNA. October 24, 2014. doi: 10.1261/rna.043968.113
• 9. A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. Cell. Volume 157, Issue 2, p369–381, 10 April 2014. DOI: 10.1016/j.cell.2014.02.019